Emerging Isotopes Pipeline Analysis and Global Market–Forecast To 2029

Publishing Date : July, 2022
Report Code : HCPH0116
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

“Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).

In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.

  • Market Analysis
    • In market analysis, global GEP-NET, Prostate cancer and  Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177,  therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
    • Emerging Isotopes related deals analysis.
    • Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
  • Pipeline Analysis
    • Pipeline Analysis based Isotopes
    • Pipeline Analysis based on indications
    • Pipeline analysis based on targets
    • Pipeline analysis based on leading players

 

  • Key Players Analysis
    • The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
    • Key players overview
    • Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
    • Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)

      “Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).

      In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.

      This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.

    • Market Analysis
      • In market analysis, global GEP-NET, Prostate cancer and  Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177,  therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
      • Emerging Isotopes related deals analysis.
      • Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
    • Pipeline Analysis
      • Pipeline Analysis based Isotopes
      • Pipeline Analysis based on indications
      • Pipeline analysis based on targets
      • Pipeline analysis based on leading players

    •  

    • Key Players Analysis
      • The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
      • Key players overview
      • Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
      • Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     REPORT SCOPE
    • 2.2     REPORT DESCRIPTION
    • 2.3     PIPELINE ANALYSIS
    • 2.4     KEY PLAYERS ANALYSIS
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
  • 3     EMERGING ISOTOPES
    • 3.1     INTRODUCTION
    • 3.2     PIPELINE ANALYSIS OVERVIEW
      • 3.2.1     DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS
      • 3.2.2     THERAPEUTIC ISOTOPES PIPELINE ANALYSIS
    • 3.3     DEMAND ANALYSIS OF EMERGING ISOTOPES
    • 3.4     LUTETIUM (LU-177)
      • 3.4.1     GEP-NET MARKET ANALYSIS
      • 3.4.2     PROSTATE CANCER MARKET ANALYSIS
      • 3.4.3     LUTETIUM PIPELINE ANALYSIS
        • 3.4.3.1     DEMAND AND PRODUCTION ANALYSIS OF LUTETIUM-177 (LU-177)
      • 3.4.4     LU-177 – DEALS, APPROVALS, AND FUNDING
    • 3.5     GALLIUM (GA-68)
      • 3.5.1     SUPPLY CHAIN ANALYSIS OF GALLIUM-68 (GA-68)
      • 3.5.2     GA-68 MARKET CHARACTERISTICS OF CURRENT GE-68/GA-68 GENERATORS
      • 3.5.3     GALLIUM-68 (GA-68) PIPELINE ANALYSIS
      • 3.5.4     GA-68 – DEALS, APPROVALS, AND FUNDING
    • 3.6     ACTINIUM (AC-225)
      • 3.6.1     PRODUCTION ANALYSIS OF ACTINIUM-225 (AC-225) AND BISMUTH-213 (BI-213)
      • 3.6.2     ACTINIUM (AC-225) PIPELINE ANALYSIS
      • 3.6.3     AC-225 – DEALS, APPROVALS, AND FUNDING
    • 3.7     YTTRIUM (Y-90)
      • 3.7.1     YTTRIUM (Y-90) PIPELINE ANALYSIS
      • 3.7.2     Y-90 – DEALS, APPROVALS, AND FUNDING
    • 3.8     ZIRCONIUM (ZR-89)
      • 3.8.1     ZIRCONIUM (ZR-89) PIPELINE ANALYSIS
      • 3.8.2     ZR-89 – DEALS, APPROVALS, AND FUNDING
    • 3.9     LEAD (PB-212)/BISMUTH (BI-212)
      • 3.9.1     LEAD (PB-212) PIPELINE ANALYSIS
      • 3.9.2     PB-212 – DEALS, APPROVALS, AND FUNDING
    • 3.10     COPPER (CU-64)
      • 3.10.1     COPPER 64 (CU-64) PIPELINE ANALYSIS
      • 3.10.2     CU-64 – DEALS, APPROVALS, AND FUNDING
    • 3.11     COPPER (CU-67)
      • 3.11.1     COPPER 67 (CU-67) PIPELINE ANALYSIS
      • 3.11.2     CU-67 – DEALS, APPROVALS, NEWS, AND FUNDING
    • 3.12     RHENIUM (RE-186)
      • 3.12.1     RHENIUM (RE-186) PIPELINE ANALYSIS
      • 3.12.2     RE-186 – DEALS, APPROVALS, NEWS, AND FUNDING
    • 3.13     RHENIUM-188 (RE-188)
      • 3.13.1     RHENIUM (RE-188) PIPELINE ANALYSIS
      • 3.13.2     RE-188 – DEALS, APPROVALS, NEWS, AND FUNDING
    • 3.14     ASTATINE (AT-211)
      • 3.14.1     ASTATINE (AT-211) PIPELINE ANALYSIS
      • 3.14.2     AT-211 – DEALS, APPROVALS, NEWS, AND FUNDING
    • 3.15     HOLMIUM (HO-166)
      • 3.15.1     HOLMIUM (HO-166) PIPELINE ANALYSIS
      • 3.15.2     HO-166 – DEALS, APPROVALS, AND NEWS
    • 3.16     RADIUM (RA-223)
      • 3.16.1     SUPPLY CHAIN ANALYSIS OF RADIUM-223 (RA-223)
      • 3.16.2     RADIUM (RA-223) PIPELINE ANALYSIS
    • 3.17     RADIUM (RA-224)
      • 3.17.1     RADIUM (RA-224) PIPELINE ANALYSIS
      • 3.17.2     RA-224 – DEALS, APPROVALS, NEWS, AND FUNDING
    • 3.18     THORIUM (TH-227)
      • 3.18.1     THORIUM (TH-227) PIPELINE ANALYSIS
    • 3.19     SCANDIUM (SC-43, 44, 47)
    • 3.20     TERBIUM (TB-149,152,155, 161)
    • 3.21     ARSENIC (AS-72, AS-74, AS-77)
    • 3.22     IRON (FE-52)
    • 3.23     BARIUM-128 (BA-128)
    • 3.24     BARIUM-131 (BA-131)
  • 4     MAJOR PLAYER PROFILES
    • 4.1     BOSTON SCIENTIFIC CORPORATION (BSC)
    • 4.2     CLARITY PHARMACEUTICALS LIMITED
    • 4.3     CURIUM SAS
    • 4.4     ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG (PENTIXAPHARM, GMBH)
    • 4.5     FUSION PHARMACEUTICALS, INC.
    • 4.6     ITM ISOTOPE TECHNOLOGIES MUNICH SE
    • 4.7     NOVARTIS AG
    • 4.8     ORANO MED, LLC
    • 4.9     PLUS THEAPEUTICS, INC.
    • 4.10     POINT BIOPHARMA GLOBAL, INC.,
    • 4.11     RADIOMEDIX, INC.,
    • 4.12     TELIX PHARMACEUTICALS, LTD.

    LIST OF TABLES

    • TABLE 1     EMERGING ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
    • TABLE 2     EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON INDICATIONS (CANCER)
    • TABLE 3     EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON INDICATIONS (NON-CANCER)
    • TABLE 4     EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • TABLE 5     EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON UNIVERSITIES/HOSPITALS
    • TABLE 6     DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON PHASES
    • TABLE 7     DIAGNOSTICS PIPELINE ANALYSIS BASED ON INDICATIONS
    • TABLE 8     DIAGNOSTICS PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • TABLE 9     DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON UNIVERSITIES/HOSPITALS
    • TABLE 10     THERAPEUTIC ISOTOPES PIPELINE ANALYSIS BASED ON PHASES
    • TABLE 11     THERAPEUTICS PIPELINE ANALYSIS BASED ON INDICATIONS
    • TABLE 12     THERAPEUTICS PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • TABLE 13     DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON UNIVERSITIES/HOSPITALS
    • TABLE 14     LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
    • TABLE 15     GEP-NET GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
    • TABLE 16     GEP-NET NUMBER OF DOSES SOLD AND PATIENTS TREATED DURING 2022
    • TABLE 17     GEP-NET THERAPY ELIGIBLE PATIENT POPULATION, BASED ON REGION, (2021-2029) (NO.S),
    • TABLE 18     GEP-NET TOTAL ADDRESSABLE MARKET (TAM) FOR GEP-NET ($MN)
    • TABLE 19     GEP-NET TOTAL DEMAND FOR DOSES IN CURIE
    • TABLE 20     GEP-NET NUMBER OF DOSES SOLD
    • TABLE 21     PROSTATE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2029) ($MN)
    • TABLE 22     PROSTATE CANCER NUMBER OF DOSES SOLD AND PATIENTS TREATED DURING 2022
    • TABLE 23     LU-177 PROSTATE CANCER THERAPY ELIGIBLE PATIENT POPULATION, BASED ON REGION, (2022-2029) (NO.S),
    • TABLE 24     LU-177 PROSTATE CANCER THERAPY TOTAL ADDRESSABLE MARKET (TAM) (2022-2029)($MN)
    • TABLE 25     LU-177 PROSTATE CANCER TOTAL DEMAND FOR DOSES IN CURIE (2022-2029)
    • TABLE 26     LU-177 PROSTATE CANCER NUMBER OF DOSES SOLD
    • TABLE 27     LUTETIUM (LU-177) SUPPLIERS AND PRODUCTION CAPACITY
    • TABLE 28     GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
    • TABLE 29     GALLIUM (GA-68) GENERATOR SUPPLIERS AND ITS CHARACTERISTICS
    • TABLE 30     ACTINIUM (AC-225) CURRENT AND FUTURE SUPPLIERS
    • TABLE 31     YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
    • TABLE 32     RENAL CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2024-2029) ($MN)
    • TABLE 33     ZR-89 RENAL CANCER DIAGNOSTIC ELIGIBLE PATIENT POPULATION, BASED ON REGION, (2022-2029) (NO.S),
    • TABLE 34     ZR-89 RENAL CANCER DIAGNOATICS TOTAL ADDRESSABLE MARKET (TAM) (2022-2029)($MN)
    • TABLE 35     ZR-89 TOTAL DEMAND FOR DOSES IN CURIE (2022-2029)
    • TABLE 36     NET GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
    • TABLE 37     CU-64 NET DIAGNOSTIC ELIGIBLE PATIENT POPULATION, BASED ON REGION, (2021-2029) (NO.S),
    • TABLE 38     CU-64 NET DIAGNOATICS TOTAL ADDRESSABLE MARKET (TAM) (2021-2029)($MN)
    • TABLE 39     CU-64 TOTAL DEMAND FOR DOSES IN CURIE (2021-2029)
    • TABLE 40     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
    • TABLE 41     ASTATINE (AT-211) CURRENT SUPPLIERS
    • TABLE 42     RADIUM (RA-223) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)

    LIST OF FIGURES

    • FIGURE 1     EMERGING ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN) AND MARKET SHARE 2022 (%)
    • FIGURE 2     EMERGING ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN), CAGR (%)
    • FIGURE 3     EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 4     EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • FIGURE 5     EMERGING ISOTOPES PIPELINE ANALYSIS BASED ON CANDIDATES AND APPLICATION
    • FIGURE 6     DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 7     DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 8     DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS BASED ON MODALITY
    • FIGURE 9     THERAPEUTIC ISOTOPES PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 10     THERAPEUTIC ISOTOPES PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 11     THERAPEUTIC ISOTOPES PIPELINE ANALYSIS, BASED ON THE TYPE OF RADIATION
    • FIGURE 12     GLOBAL LU-177 BASED THERAPY MARKET PENETRATION, (2022) (%)
    • FIGURE 13     NORTH AMERICA LU-177 BASED THERAPY MARKET PENETRATION, (2022) (%)
    • FIGURE 14     EUROPE LU-177 BASED THERAPY MARKET PENETRATION, (2022) (%)
    • FIGURE 15     ASIA-PACIFIC LU-177 BASED THERAPY MARKET PENETRATION, (2022) (%)
    • FIGURE 16     ROW LU-177 BASED THERAPY MARKET PENETRATION, (2021) (%)
    • FIGURE 17     PROSTATE CANCER GLOBAL MARKET PENETRATION, (2022) (%)
    • FIGURE 18     NORTH AMERICA PROSTATE CANCER MARKET PENETRATION, (2022) (%)
    • FIGURE 19     EUROPE PROSTATE CANCER MARKET PENETRATION, (2022) (%)
    • FIGURE 20     ASIA-PACIFIC PROSTATE CANCER MARKET PENETRATION, (2022) (%)
    • FIGURE 21     ROW PROSTATE CANCER MARKET PENETRATION, (2022) (%)
    • FIGURE 22     LU-177 PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 23     LU-177 PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 24     LU-177 PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 25     LU-177 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • FIGURE 26     LU-177 PIPELINE ANALYSIS BASED ON MOLECULE TYPE
    • FIGURE 27     LU-177 RIT PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 28     LU-177 RIT PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 29     LU-177 RIT PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 30     LU-177 PRRT PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 31     LU-177 PRRT PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 32     LU-177 PRRT PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 33     DIRECT METHOD (CARRIER ADDED)
    • FIGURE 34     INDIRECT METHOD (NON-CARRIER ADDED)
    • FIGURE 35     GA-68: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
    • FIGURE 36     SUPPLY CHAIN OF GE-68/GA-68 GENERATOR
    • FIGURE 37     GA-68 PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 38     GA-68 PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 39     GA-68 PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 40     GA-68 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • FIGURE 41     GA-68 PIPELINE ANALYSIS BASED ON MOLECULE TYPE
    • FIGURE 42     AC-225 PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 43     AC-225 PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 44     AC-225 PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 45     AC-225 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • FIGURE 46     AC-225 PIPELINE ANALYSIS BASED ON MOLECULE TYPE
    • FIGURE 47     Y-90 PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 48     Y-90 PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 49     Y-90 PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 50     Y-90 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • FIGURE 51     Y-90 PIPELINE ANALYSIS BASED ON MOLECULE TYPE
    • FIGURE 52     ZR-89 PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 53     ZR-89 PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 54     ZR-89 PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 55     ZR-89 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • FIGURE 56     ZR-89 PIPELINE ANALYSIS BASED ON MOLECULE TYPE
    • FIGURE 57     PB-212 PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 58     PB-212 PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 59     PB-212 PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 60     PB-212 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • FIGURE 61     PB-212 PIPELINE ANALYSIS BASED ON MOLECULE TYPE
    • FIGURE 62     CU-64 PIPELINE ANALYSIS BASED ON PHASES
    • FIGURE 63     CU-64 PIPELINE ANALYSIS BASED ON INDICATIONS
    • FIGURE 64     CU-64 PIPELINE ANALYSIS BASED ON TARGETS
    • FIGURE 65     CU-64 PIPELINE ANALYSIS BASED ON MAJOR PLAYERS
    • FIGURE 66     CU-64 PIPELINE ANALYSIS BASED ON MOLECULE TYPE
    • FIGURE 67     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
    • FIGURE 68     BOSTON SCIENTIFIC CORPORATION (BSC)
    • FIGURE 69     CLARITY PHARMACEUTICALS LIMITED
    • FIGURE 70     CURIUM SAS
    • FIGURE 71     ECKERT & ZIEGLER (PENTIXAPHARM, GMBH)
    • FIGURE 72     FUSION PHARMACEUTICALS, INC.
    • FIGURE 73     ITM (ISOTOPE TECHNOLOGIES MUNICH)
    • FIGURE 74     NOVARTIS AG
    • FIGURE 75     ORANO MED, LLC
    • FIGURE 76     PLUS THEAPEUTICS, INC.
    • FIGURE 77     POINT BIOPHARMA GLOBAL, INC.
    • FIGURE 78     RADIOMEDIX, INC.
    • FIGURE 79     TELIX PHARMACEUTICALS, LTD.

    LIST OF COMPANIES MENTIONED IN THE REPORT

    • 1     ACTINIUM PHARMACEUTICALS
    • 2     ALPHA TAU MEDICAL LTD.
    • 3     BAYER
    • 4     BOSTON SCIENTIFIC CORP.
    • 5     CANCER TARGETED TECHNOLOGY
    • 6     CANPROBE
    • 7     CELL THERANOSTICS
    • 8     CLARITY PHARMACEUTICALS LTD
    • 9     CLOVIS ONCOLOGY
    • 10     CURIUM SAS
    • 11     DEBIOPHARMA GROUP
    • 12     E&Z (PENTIXAPHARM)
    • 13     EXCEL DIAGNOSTICS AND NUCLEAR ONCOLOGY CENTER
    • 14     FIVE ELEVEN PHARMA, INC.
    • 15     FUSION PHARMACEUTICALS
    • 16     FUTURECHEM
    • 17     IMAGINAB,INC
    • 18     ISOTOPE TECHNOLOGIES MUNICH A.G.
    • 19     JOHNSON & JOHNSON (JANSSEN R & D, LLC)
    • 20     MOLECULAR TARGETING TECHNOLOGIES INC.
    • 21     MONOPAR THERAPEUTICS
    • 22     NAMI THERAPEUTICS
    • 23     NANOMAB
    • 24     NORDIC NANOVECTOR ASA
    • 25     NOVARTIS AG
    • 26     NUVIEW LIFE SCIENCES, INC.
    • 27     ONCOINVENT AS
    • 28     ONCOONE RESEARCH & DEVELOPMENT GMBH
    • 29     ONCOTHERAPY SCIENCE, INC.
    • 30     ORANOMED
    • 31     PLUS THERAPEUTICS
    • 32     POINT BIOPHARMA
    • 33     PRECISION MOLECULAR
    • 34     RADIOMEDIX
    • 35     RADIOPHARM THERANOSTICS
    • 36     SCINTOMICS
    • 37     SINOTAU PHARMACEUTICAL GROUP
    • 38     SOFIE BIOSCIENCES
    • 39     TELIX INTERNATIONAL PTY LTD
    • 40     VIEWPOINT MOLECULAR TARGETING
    • 41     Y-MABS THERAPEUTICS